A Comprehensive Review and Update on Cannabis Hyperemesis Syndrome.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing pathophysiological mechanisms and management without systematic review methodology or primary data
PubMed 39598458 · doi:10.3390/ph17111549
What was done
This narrative review synthesizes current literature on cannabis hyperemesis syndrome (CHS). It examines the pathophysiological mechanisms involving the endocannabinoid system (including cannabinoid type 1 receptor inhibition of gastrointestinal motility and thermoregulatory dysfunction), diagnostic overlap with cyclical vomiting syndrome, and general management strategies.
What was found
The abstract provides no quantitative data or specific outcome statistics. It reports qualitatively that cannabis contains over 400 chemical entities and 100 cannabinoids with biphasic emetic properties (anti-emetic at low doses, pro-emetic at high doses), and attributes compulsive hot bathing behaviors to endocannabinoid-mediated thermoregulatory effects.
Why it matters
As recreational cannabis legalization expands, CHS incidence is anticipated to grow; clarifying its clinical features and gut-brain mechanisms aids in reducing frequent misdiagnosis.
Limits
The abstract reports no primary clinical data, quantitative meta-analytic pooling, or structured systematic search criteria. Exact diagnostic sensitivity, treatment outcomes, and prevalence rates are not quantified.
Cited by
- supports Chronic cannabis exposure can lead to cannabinoid hyperemesis syndrome, causing cyclical vomiting despite initial anti-emetic effects.